BCL2 Gene: Function, Mutations, and Clinical Significance | Biomedical SEO

The BCL2 gene encodes an integral outer mitochondrial membrane protein that blocks apoptotic death by inhibiting pro-apoptotic BAX and BAK, thereby promoting cell survival. Overexpression of BCL2 prevents programmed cell death and is a hallmark of many cancers, particularly follicular lymphoma and chronic lymphocytic leukemia. BCL2 also regulates autophagy and calcium homeostasis. Its function is modulated by phosphorylation and interactions with BH3-only proteins. The gene is a direct target of the transcription factor p53 and is frequently dysregulated by chromosomal translocations, such as t(14;18), leading to constitutive overexpression. BCL2 is a validated therapeutic target, with BH3 mimetics like venetoclax used clinically.

Tissue Expression

Cell Line Expression

Hotspot Mutations

Mutation functional classification

• Apoptosis

• Intrinsic Pathway for Apoptosis

• BCL2 family-mediated apoptosis

• p53 signaling pathway

• PI3K-Akt signaling pathway

• Regulation of autophagy

The BCL2 protein (UniProt P10415) is a 239-amino-acid integral membrane protein localized to the outer mitochondrial membrane, endoplasmic reticulum, and nuclear envelope. It contains a C-terminal transmembrane domain and a BH1, BH2, BH3, and BH4 homology domain. BCL2 heterodimerizes with pro-apoptotic BAX and BAK, preventing their oligomerization and mitochondrial outer membrane permeabilization, thus blocking cytochrome c release and caspase activation. It also interacts with BH3-only proteins (e.g., BAD, BID) to sequester them. BCL2 is phosphorylated by kinases such as ERK and JNK, modulating its anti-apoptotic function. The protein has a long half-life and is regulated by ubiquitination and proteasomal degradation. Its overexpression is a key oncogenic event in many B-cell malignancies.